NCT04148742 - Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3) | Biotech Hunter

Timeline

Start Date

August 31, 2021

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions

Non-Hodgkin's B-cell Lymphoma

Interventions

DRUG

DZD9008

Daily dose of DZD9008, except for cycle 0 of Part A, in which a single dose of DZD9008 is administrated. Starting dose of DZD9008 is 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008.

Trial Locations (2)

Unknown

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Nanjing

Jiangsu Province Hospital - Haematology, Nanjing